Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The reactivity of a new monoclonal antibody (MAb), MSN-1, raised against a human endometrial cancer cell line (SNG-II), was studied in a variety of endometrial, endocervical, and ovarian carcinomas as well as normal cycling endometrium. Moderate to strong reactivity (2-3+) was seen in six of nine normal secretory endometria (67%), one of 10 normal proliferative endometria (10%), 18 of 18 endometrial adenocarcinomas (100%), 10 of 11 endometrioid ovarian adenocarcinomas (91%), seven of nine clear cell ovarian adenocarcinomas (78%), one of 12 endometrial hyperplasias without atypia (9%), two of four endometrial hyperplasias with atypia (50%), zero of five endometrial serous adenocarcinomas, two of 17 serous ovarian adenocarcinomas (12%), zero of 10 intestinal-type mucinous ovarian adenocarcinomas, and zero of nine metastatic adenocarcinomas in ovary. Endocervical adenocarcinomas showed moderate to strong staining in 75% (six of eight). It is concluded that MSN-1 can be used to confirm endometrioid/clear cell differentiation in ovarian and endometrial tumors, cannot be used to discriminate endocervical from endometrial differentiation, cannot be used to discriminate atypical hyperplasia from carcinoma, and may be useful to distinguish between atypical (premalignant) endometrial hyperplasias and those without atypia.
 ...
PMID:MSN-1 antibody in the evaluation of female genital tract adenocarcinomas. 229 65

To determine a phenotypic difference between normal endometrium and endometrial adenocarcinoma, a new monoclonal antibody (MSN-1) was produced by immunizing a new endometrial cancer cell line (SNG-II), which was established in 1981 from a 43-year-old Japanese woman with stage II uterine endometrial cancer. MSN-1 recognized the Lewis-b carbohydrate moiety on the cell surface glycolipid and seldom reacted immunohistochemically with normal endometrium but with about 90% of endometrial cancer cases. By application of MSN-1 to flow cytometry, the possibility of differentiating endometrial normal cells from cancer cells was demonstrated.
 ...
PMID:A monoclonal antibody (MSN-1) against a newly established uterine endometrial cancer cell line (SNG-II) and its application to immunohistochemistry and flow cytometry. 238 76

The possibility of a genetic relationship between ovarian, breast, and endometrial cancer was investigated in data from a large multicenter, population-based, case-control study, the Cancer and Steroid Hormone Study conducted by the Centers for Disease Control (CDC). Age-adjusted relative risks (RRs) for mothers and sisters of 493 ovarian cancer cases, 895 breast cancer cases, and 143 endometrial cancer cases versus 4,754 controls were calculated. Significantly elevated age-adjusted RRs were found for ovarian cancer (RR = 2.8; 95% confidence interval [CI] = 1.6-4.9) and breast cancer (RR = 1.6; 95% CI = 1.1-2.1) among relatives of ovarian cancer probands and for breast cancer (RR = 2.1; 95% CI = 1.7-2.5) and ovarian cancer (RR = 1.7; 95% CI = 1.0-2.0) among relatives of breast cancer probands. Relatives of endometrial cancer probands had an elevated RR for endometrial cancer only (RR = 2.7; 95% CI = 1.6-4.8). The genetic relationship between ovarian, breast, and endometrial cancer was tested using a multivariate polygenic threshold model developed by Smith (1976), which was modified to accommodate three classes of probands. Estimates of heritability for ovarian, breast, and endometrial cancer were 40%, 56%, and 52%, respectively. There was a significant genetic correlation between ovarian and breast cancer (R12 = .484). Evidence for significant genetic overlap between endometrial cancer and either ovarian or breast cancer was not found. These results suggest the existence of a familial breast/ovarian cancer syndrome. Endometrial cancer, while heritable, appears to be genetically unrelated.
 ...
PMID:Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. 249 Oct 11

A human monoclonal antibody termed HMST-1 was produced by fusing lymphocytes from segments of human pelvic lymph nodes from an endometrial cancer patient with murine myeloma cells. The epitope recognized by HMST-1 was determined to be lacto-series type 1 chain-containing glycosphingolipid (Gal beta 1-3GlcNAc beta 1-3Gal beta 1-4Glc beta 1-1Cer) by isolating the antigen from endometrial cancer cell line SNG-II and analyzing with fast atom bombardment mass spectrometry, permethylation analysis, and exoglycosidase treatment. By the immunohistochemical avidin-biotin-peroxidase complex method, no normal endometrium and benign endometrial hyperplasia were stained with HMST-1, but HMST-1 reacted with about 35% of endometrial cancer cases. These facts indicate that the rate of expression of the antigen increases along with the course of malignancy in the endometrium. By sialidase treatment of the section, the positive rate increased to 57% in endometrial cancers and to 13% in normal endometrium, indicating that the antigen was masked with sialic acid and exposed by neuraminidase treatment. Immunohistochemistry also revealed that the antibody reacted with human fetal alimentary tract epithelium and mesothelium, indicating the oncodevelopmental nature of Gal beta 1-3GlcNAc beta 1-3Gal beta 1-4Glc beta 1-1Cer.
 ...
PMID:Human monoclonal antibody (HMST-1) against lacto-series type 1 chain and expression of the chain in uterine endometrial cancers. 268 63

Since cultured cells have the possibility to produce tumor-associated substances in vitro, we generated several monoclonal antibodies using cultured cells as immunogen and applied them to cancer diagnosis. Two monoclonal antibodies (F602-1 and F602-6) were generated against a newly established ovarian mesonephroid cancer cell line (RMG-II), and a double determinants sandwich enzyme-immunoassay system was developed. Their epitopes were proved to exist on the CA125 molecules, but to be different from the one recognized by OC125, and almost the same result of serum assay as CA125 was obtained by this assay. A new monoclonal antibody (MSN-1) was produced by immunizing a new endometrial cancer cell line (SNG-II). MSN-1 recognized the Lewis-b carbohydrate moiety on the cell surface glycolipid, and seldom reacted immunohistochemically with normal endometrium, but reacted with about 90% of endometrial cancer cases. By application of MSN-1 to flow-cytometry, the possibility of differentiating endometrial normal cells from the cancer cells was demonstrated.
 ...
PMID:[Monoclonal antibodies raised against cultured cells and their application in cancer diagnosis]. 273 79

Glycosphingolipids, which have recently attracted attention due to their biological significance in cell membrane, human uterine endometrium and endometrial cancer cell lines were analyzed biochemically. Among the neutral and acidic glycosphingolipids in uterine endometrium, the concentration of sulfatide, I3Sulfo-GalCer, significantly increased 16-fold from the proliferative to the secretory phases of the menstrual cycle, suggesting that sex steroid hormones induce sulfotransferase, which is responsible for the synthesis of sulfatide. On the other hand, SNG-II and SNG-M derived from endometrial adenocarcinoma showed a predominant synthetic capacity for I3Sulfo-LacCer and II3Sulfo-Gg3Cer. The apparent Km of cerebroside sulfotransferase in SNG-II was about 60 microM, whereas gynecological cancer cell lines established from different regions of the tumor did not show a synthetic capacity for sulfoglycolipids. The present study suggested that sulfoglycolipids are closely related to the cell function of uterine endometrium in association with sex steroid hormones, and that endometrial cancer cell lines are useful in investigating the biological functions of sulfoglycolipids.
 ...
PMID:[Glycosphingolipids in human uterine endometrium: expression of sulfoglycolipids and its fluctuation during menstrual cycle]. 274 66

The present study was designed to examine the immunotherapeutic properties of lymphokine-activated killer (LAK) cells against uterine endometrial cancers. Three endometrial cancer cell lines, ISHIKAWA, SNG-M, and HHUA, were shown to be specifically lysed in short-term 51Cr-release assay, although the susceptibility was different among the cell lines. The xenograft tumors of ISHIKAWA and SNG-M exhibited high susceptibility to LAK cells in the in vitro assay and responded well to the adoptive transfer of LAK cells in nude mice. On the other hand, the xenograft of HHUA showed low reactivity to LAK cells and showed no response to the adoptive immunotherapy. However, the adoptive transfer of LAK cells combined with intraperitoneal administration of both recombinant interleukin-2 (rIL-2) and lentinan markedly inhibited the growth of HHUA xenografts in nude mice, while no response was observed in nude mice treated with LAK cells plus either rIL-2 or lentinan, or treated with rIL-2 plus lentinan alone. These results suggest the clinical application of adoptive immunotherapy in association with LAK cells, rIL-2, and lentinan as a treatment of gynecologic cancers.
 ...
PMID:Adoptive cellular immunotherapy to the endometrial carcinoma cell line xenografts in nude mice. 278 71

Effects of prostaglandin F2 alpha, E2, D2 and J2 on the DNA and RNA contents of a human endometrial cancer cell lines (SNG and Ishikawa) were studied using flow cytometry. Cytotoxic effects of various prostaglandins on SNG and Ishikawa cell lines were examined and PG J2 and PG D2 were found most active. Among other prostaglandins PG E2 showed a comparable inhibitory activity to cellular growth but PG F2 alpha didn't. In SNG and Ishikawa cell lines after RNase treatment, PG J2, PG D2 and PG E2 caused a decrease of the S-phase and G2 + M-phase cell population in cell cycle. On the other hand, PG F2 alpha caused a increase of the S-phase cell population in cell cycle PG J2, PG D2 and PG E2 after DNase treatment caused a decrease of the relative RNA content in both of cell lines. On the other hand, PG F2 alpha caused a increase of the relative RNA content. It is a noteworthy that PG J2 and PG D2 were remarkably recognized delay of doubling time and decrease of survival fraction under the time and dose dependence. These effects occur not only by direct lethal influence of the prostaglandins, but also by substantially inhibit RNA and DNA synthesis with a delay of the cell cycle. These results might be suggested a role for prostaglandin J2 and D2 in the regulation of growth of endometrial adenocarcinoma cells.
 ...
PMID:[Inhibition of growth of human endometrial adenocarcinoma cells in vitro treated with prostaglandin F2 alpha, E2, D2 and J2]. 346 9

An increased rate of expression of Lewis group antigens, particularly Lewisb antigen, was observed in endometrial cancers compared with its expression in normal endometria. In order to elucidate the expression mechanism of Lewisb antigen in endometrial cancer, the level of fucosyltransferase (FT) was examined. The levels of alpha 1-2FT alpha 1-3FT and alpha 1-4FT were higher in endometrial cancer than those in normal endometrium. Endometrial cancer with a poor prognosis tended to react poorly to anti-endometrial cancer monoclonal antibody designated MSN-1, suggesting the possibility that the reactivity to MSN-1 is useful as a new prognostic factor for endometrial cancer. Cells of uterine endometrial cancer cell line SNG-II were classified into two groups according to their reactivity with MSN-1, whose antigen recognized is mainly Lewisb antigen. Using these classified cells of endometrial cancer cell line, it has revealed that the cells which strongly express H type antigen have more tendency to attach to endothelial cells and to cause metastasis than the cells which strongly express Lewisb antigen.
 ...
PMID:[Abnormal expression of carbohydrate chain and its mechanism in endometrial cancer]. 763 16

The in vitro invasive ability, the expression of cell adhesion molecule E-cadherin, activity of matrix metalloproteinase (MMP) and K-ras point mutation were investigated in eight human endometrial carcinoma cell lines. 1) In vitro invasive abilities of endometrial carcinoma cell lines depend on the degree of cell differentiation and the origin of cell lines. A poorly-differentiated carcinoma cell line (NUE-1) and a cell line derived from metastatic lymph node (SNG-M) were more invasive than moderately-(HEC-1A, HEC-1BE) and well-differentiated (HEC-6, Ishikawa) cell lines. 2) Immunohistochemically, less or non-invasive cell lines expressed E-cadherin strongly, whereas a highly invasive cell line (NUE-1) expressed E-cadherin weakly. 3) When cultured on Matrigel-coated dishes, the tumor cells derived from moderately- and well-differentiated carcinoma aggregated with each other and did not invade Matrigel in the invasion assay. The aggregated cells expressed E-cadherin more strongly when cultured on Matrigel. 4) 72-kD gelatinase (MMP-2) was secreted in serum-free conditioned medium of all cell lines. In an invasive cell line (NUE-1,SNG-M), the activity of MMP-2 was stronger than in other cell lines. And the activity of 92-kDa gelatinase (MMP-9) was detected in most invasive cell line (NUE-1). 5) Point mutation of K-ras codon 12 was detected in four of eight (50%) cell lines by the PCR-RFLP method. The changes in the DNA sequence were identified, but K-ras point mutation was not correlated with in vitro invasiveness of the tumor cells.
 ...
PMID:[The factors involved in invasive ability of endometrial carcinoma cells]. 804 Jun 23


1 2 3 Next >>